The Latest News
-
Children's Health
New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease
Elusive liver stem cells found ‘outside the box’ offer a ray of light to people with Alagille syndrome. -
Genetic Disorders and Aging
How Sanford Burnham Prebys is helping map the brain
As a principal investigator in the NIH's BRAIN/BICCN Initiative, Jerold Chun, M.D., Ph.D. and his team are part of a global collaboration to demystify the human brain to help better treat its diseases and disorders. -
Children's Health
How microbes shape human health: an interview with Andrei Osterman
Microbes living in and on our bodies are key players in our health, and their power can be harnessed to enhance it. -
The annual event provides valuable presentation experience to scientists at the beginning of their research careers. -
The Fishman Fund Awards were presented on September 23, 2021, in a virtual ceremony that honored the enduring legacy of our Institute’s founders, Dr. William and Lillian Fishman. -
Immunity
Jamey Marth awarded $13.5 million by NIH to investigate the pathogenesis and treatment of sepsis
The grant was awarded to Marth to continue his team’s groundbreaking research on the molecular mechanisms of sepsis with the goal of achieving more effective treatments. -
A new grant awarded to faculty from Sanford Burnham Prebys and the Salk Institute will fund a five-year project to explore the connection between aging and liver cancer with the goal of developing new therapeutic approaches. -
Genetic Disorders and Aging
NASA awards $2 million to study effects of low gravity on muscle and neuron function
The three-year grant to assistant professor Karen Ocorr will study the model organisms of fruit flies and nematode worms aboard the International Space Station. -
Eric Wang, Ph.D., has joined our NCI-designated Cancer Center an assistant professor in the Tumor Initiation and Maintenance Program. His lab will focus on using and developing chemical tools to influence the activity of tumor and immune cells. -
Cancer
Endeavor Biomedicines licenses ULK1/2 inhibitor from Sanford Burnham Prebys and the Salk Institute
The exclusive agreement with Endeavor Biomedicines is for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1/2, a protein involved in cell recycling. -
RNF5 is required for AML growth. The protein could be inhibited or used as a biomarker to improve patient outcomes. -
A drug discovered in the lab of Nicholas Cosford, Ph.D., professor and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys, has entered a Phase 1 clinical study.
Living History
NCI-Designated Cancer Center
Earning the NCI designation in 1981 — just five years after its modest start in downtown La Jolla — our Cancer Center truly is "the miracle on Torrey Pines Mesa."
Next Generation
Victoria Blaho receives prestigious Lina M. Obeid Award
Victoria Blaho, Ph.D., assistant professor in the Immunity and Pathogenesis Program, has received the first-ever Lina M. Obeid Award for her promising research on the biology of sphingolipids.
Living History
Along the road to discovery
It was in 1979 when Eva Engvall asked Erkki Ruoslahti a question that would change their lives forever: "Wouldn't it be great to work in San Diego?"
Next Generation
Graduate student Katja Birker's research doesn't miss a beat
"There is no magic wand to cure congenital heart conditions–we have to do the research."
COVID-19 matching gift campaign
The power of investing in human health
Dinah Ruch is accelerating our COVID-19 efforts with a generous matching gift that doubles all donations dollar for dollar up to $500,000.
Our Partners in Discovery
We can't do it alone
Our annual Rare Disease Day symposium strengthens the global network of families, physicians and researchers to better understand and fight rare diseases in children.
Our Partners in Discovery
Getting to the finish line faster
Thanks to the philanthropic vision of Stuart and Karen Tanz, a unique collaboration seeks new treatments for diseases such as Alzheimer’s, dementia and Parkinson’s.
Our Partners in Discovery
New hope for autoimmune disease
Our partnership with Lilly—centered around a high degree of interaction—has already produced an immune therapy now in clinical trial.
Our Partners in Discovery
A master class in collaboration
Meet T. Denny Sanford, Conrad Prebys and Malin Burnham: three people who know we're stronger when we work together.
